Research at a glance.
Four evidence clusters.
Pre-Clinical Research
In-vitro and animal research on gastric mucosal protection, diarrheal support, cholesterol reduction, collagenase inhibition and antioxidant activity.
Clinical Research
Human research published on B. coagulans strains, presented as species-level evidence alongside the strain-specific Bacospore® programme.
Additional Functional Properties
Antioxidant, cholesterol-lowering, collagenase-inhibiting and cellular-metabolic activity broaden the potential of Bacospore® for multifunctional formulations.
Safety, Quality & Toxicology
Bacospore® 300B is released against defined heavy-metal, microbiological, GMO-free and BSE/TSE-free specifications.
Study index.
| Year | Study | Model | Key outcome |
|---|---|---|---|
| 2026 | Strain-Specific Modulation of Oxidative Stress, Carbohydrate Metabolism and Adipogenesis by Probiotic Bacillus spp. in 3T3-L1 Cells | 3T3-L1 cells, four Bacillus strains | Strongest antioxidant activity of the four strains; high cell viability. |
| 2026 · in press | Evaluation of Antidiarrheal, Antiulcer, Anti-Collagenase and Cholesterol-Lowering Activity of Heyndrickxia coagulans MTCC 25308 | Ethanol-ulcer & castor-oil diarrhoea in rats; in-vitro assays | 80.4% ulcer inhibition · 26.6% diarrhoea inhibition · 85.40% collagenase · 97.72% cholesterol reduction. |
How we label our evidence.
Probiotic activity is strain-specific, so every study on this site is labelled by the exact strain evaluated. Strain-specific findings on MTCC 25308 come from animal, cellular and laboratory models. Human research on other B. coagulans strains is presented separately as species-level evidence. These statements have not been evaluated by the FDA or EFSA, and Bacospore® is not intended to diagnose, treat, cure or prevent any disease.